CRISPR Therapeutics AG — Director's Dealing 2016

Oct 18, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: Hadley Harbor Master Investors (Cayman) L.P. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Convertible Preferred Shares	$		Common Shares (744380)		Direct

Footnotes

F1: The Series B Convertible Preferred Shares are convertible into CRISPR Therapeutics AG common shares on a one-for-one basis and have no expiration date.